1. Home
  2. KD vs LEGN Comparison

KD vs LEGN Comparison

Compare KD & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$26.71

Market Cap

5.8B

Sector

Technology

ML Signal

HOLD

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$22.09

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
LEGN
Founded
2020
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.9B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KD
LEGN
Price
$26.71
$22.09
Analyst Decision
Buy
Strong Buy
Analyst Count
5
13
Target Price
$39.60
$69.67
AVG Volume (30 Days)
2.0M
2.6M
Earning Date
02-02-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.68
N/A
Revenue
$15,008,000,000.00
$909,045,000.00
Revenue This Year
$6.40
$68.83
Revenue Next Year
$3.60
$51.27
P/E Ratio
$16.03
N/A
Revenue Growth
N/A
74.75
52 Week Low
$23.28
$22.28
52 Week High
$44.20
$45.30

Technical Indicators

Market Signals
Indicator
KD
LEGN
Relative Strength Index (RSI) 52.50 21.15
Support Level $26.51 $26.43
Resistance Level $27.84 $28.97
Average True Range (ATR) 0.71 1.36
MACD 0.28 -0.45
Stochastic Oscillator 65.65 2.51

Price Performance

Historical Comparison
KD
LEGN

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: